Use of Janus Kinase Inhibitors in the Treatment of Genodermatoses: A Systematic Review
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/5123844 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 28.07.2026. Verfasst von Pin-Chun Chen und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Veterans General Hospital.
Abstract (Originalsprache)
Introduction
Genodermatoses are rare inherited skin disorders with limited treatment options. Emerging evidence suggests Janus kinase (JAK) inhibitors may offer therapeutic benefits by modulating underlying immune and inflammatory pathways. This study aims to systematically review the efficacy and safety of JAK inhibitors in treating genodermatoses, including epidermolysis bullosa (EB), Netherton syndrome, and Hailey‐Hailey disease.
Methods
A comprehensive literature search identified case reports and series evaluating JAK inhibitor therapy in genodermatoses. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal Tools for Case Reports, demonstrating high methodological quality across included studies.
Results
Twenty studies involving patients with EB subtypes (especially dystrophic EB), Netherton syndrome, and other inherited dermatoses reported clinical improvement following treatment with JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. Outcomes included reduction in pruritus, skin inflammation, and lesion severity, with notable improvements in quality‐of‐life measures. Treatment regimens varied (e.g., tofacitinib 5 mg twice daily, baricitinib 2 mg once daily, and upadacitinib 15 mg once daily) with follow‐up ranging from weeks to months. Laboratory monitoring showed stable profiles without significant adverse events. Reports of adverse events were rare or absent across studies, indicating favorable safety profiles.
Conclusions
JAK inhibitors represent a promising therapeutic avenue for genodermatoses characterized by immune dysregulation and chronic inflammation. While preliminary data are encouraging, further controlled studies are warranted to establish long‐term efficacy and safety. These findings support expanded clinical investigation of JAK inhibition in managing inherited skin disorders.
Förderung
- Taipei Veterans General Hospital
Zitieren
APA
Chen, P., Chen, C., Ma, S., & Chen, T. (2026). Use of Janus Kinase Inhibitors in the Treatment of Genodermatoses: A Systematic Review. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/5123844
Vancouver
Chen P, Chen C, Ma S, Chen T. Use of Janus Kinase Inhibitors in the Treatment of Genodermatoses: A Systematic Review. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/5123844
BibTeX
@article{Chen2026,
author = {Chen, Pin-Chun and Chen, Chih-Chiang and Ma, Sheng-Hsiang and Chen, Tai-Li},
title = {Use of Janus Kinase Inhibitors in the Treatment of Genodermatoses: A Systematic Review},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/5123844}
}
EUVIMED